- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.09. | Biosergen AB - Removal from trading on Nasdaq First North Growth Market | 363 | GlobeNewswire | Biosergen AB has applied for its shares to be removed from trading on Nasdaq First North Growth Market.
Conditional upon the Swedish Companies Registration Office's authorization to implement... ► Artikel lesen | |
| 17.09. | Biosergen AB: Nasdaq approves Biosergen's application for delisting from First North Growth Market conditional upon the Swedish Companies Registration Office granting permission to execute the merger with Flerie | 259 | GlobeNewswire (Europe) | Biosergen AB ("Biosergen" or the "Company") applied on 15 September 2026 for delisting of the Company's shares from Nasdaq First North Growth Market, in connection with the contemplated merger between... ► Artikel lesen | |
| 15.09. | Biosergen AB: Biosergen applies for delisting of the company's shares from Nasdaq First North Growth Market conditional upon completion of the merger with Flerie | 197 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB ("Biosergen" or the "Company") has today, on 15 September 2026, in connection with the contemplated merger between Biosergen and Flerie AB (publ) ("Flerie") (the... ► Artikel lesen | |
| BIOSERGEN Aktie jetzt für 0€ handeln | |||||
| 10.09. | Biosergen AB: Biosergen resolves on a set-off issue to guarantors in connection with the completed rights issue | 137 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB (publ) ("Biosergen" or the "Company") has today, on 10 September 2026, pursuant to the authorisation granted by the extraordinary general meeting held on 6 August... ► Artikel lesen | |
| 28.08. | Biosergen AB: Biosergen's Rights Issue Oversubscribed | 391 | GlobeNewswire (Europe) | Biosergen AB (publ) ("Biosergen" or the "Company") today announces the outcome of the rights issue of shares (the "Rights Issue") for which the subscription period ended on 26 August 2026. The final... ► Artikel lesen | |
| 19.08. | Biosergen AB: Biosergen publishes interim report for the first half year 2026 | 318 | GlobeNewswire (Europe) | Biosergen Secures Funding Through Planned Merger Together with Flerie
August 19, 2026: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the first half of 2026. The... ► Artikel lesen | |
| 11.08. | Listing of subscription rights and paid subscription shares of Biosergen AB | 487 | GlobeNewswire | With effect from August 12, 2026, the subscription rights in Biosergen AB will be traded on First North Growth Market. Trading will continue up until and including August 21, 2026.
... ► Artikel lesen | |
| 10.08. | Biosergen AB: Biosergen publishes information document regarding rights issue | 406 | GlobeNewswire (Europe) | The Board of Directors of Biosergen AB (publ) ("Biosergen" or the "Company") has today, on 10 August 2026, published an information document in connection with the rights issue of shares of approximately... ► Artikel lesen | |
| 06.08. | Biosergen AB: Bulletin from the extraordinary general meeting of Biosergen AB (publ) | 363 | GlobeNewswire (Europe) | Biosergen AB, reg. no. 559304-1295 ("Biosergen" or the "Company"), held its extraordinary general meeting today, 6 August 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the... ► Artikel lesen | |
| 06.08. | XFRA CAPITAL ADJUSTMENT INFORMATION - 06.08.2026 | 402 | Xetra Newsboard | Das Instrument W1M SG1J24887775 SINGAPORE SHIPPING SD-,1 EQUITY wird cum Kapitalmassnahme gehandelt am 06.08.2026 und ex Kapitalmassnahme am 07.08.2026 The instrument W1M SG1J24887775 SINGAPORE SHIPPING... ► Artikel lesen | |
| 16.07. | BIOSERGEN AB: Flerie publishes merger document | 8 | Cision News | ||
| 08.07. | Notice of extraordinary general meeting in Biosergen AB | 2 | Cision News | ||
| 30.06. | Biosergen AB: Bulletin from the annual general meeting of Biosergen AB | 242 | GlobeNewswire (Europe) | Biosergen AB reg. no. 559304-1295 ("Biosergen" or the "Company") held its annual general meeting today, 30 June 2026, at BAHR Advokatbyrå, Birger Jarlsgatan 16, 114 34 Stockholm, where the below resolutions... ► Artikel lesen | |
| 29.06. | The observation status for Biosergen AB is updated | 318 | GlobeNewswire | On April 10, 2026, the shares in Biosergen AB (the "Company") were given observation status with reference to information that the Company's board of directors had resolved to pause the development... ► Artikel lesen | |
| 26.06. | Biosergen AB: Statement from the Board of Directors of Biosergen regarding the merger with Flerie | 1.175 | GlobeNewswire (Europe) | This statement is made by the Board of Directors of Biosergen AB (the "Company" or "Biosergen") pursuant to Section II.19 of the Swedish takeover rules for certain trading platforms (the "Takeover... ► Artikel lesen | |
| 26.06. | Biosergen AB: The Board of Directors of Biosergen has resolved on a rights issue of shares of approximately SEK 40 million in connection with the merger with Flerie | 399 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE,... ► Artikel lesen | |
| 26.06. | BIOSERGEN AB: Biosergen Publishes 2025 Annual Report | 1 | Cision News | ||
| 26.06. | Flerie AB: Flerie and Biosergen have agreed on a merger plan - Flerie's first new investment since its listing on Nasdaq Stockholm | 492 | GlobeNewswire (Europe) | Today, on 26 June 2026, Flerie AB (publ) ("Flerie") and Biosergen AB ("Biosergen") (together the "Companies") jointly announce that the Board of Directors of Flerie and the Board of Directors of Biosergen... ► Artikel lesen | |
| 11.06. | Notice of annual general meeting in Biosergen AB | 2 | Cision News | ||
| 10.04. | Biosergen AB receives observation status | 393 | GlobeNewswire | On April 4, 2026, Biosergen AB ("the Company") disclosed that the Company's board of directors had resolved to pause the development of BSG005 and that the board of directors is exploring the possibility... ► Artikel lesen |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,955 | +0,31 % | Heidelberg Materials schwächelt weiter, Qiagen zieht an: DAX-Ausblick | Der DAX bleibt im Konsolidierungsmodus. Nach einer zwischenzeitlichen Erholung geriet das größte deutsche Börsenbarometer am Freitag wieder unter Abgabedruck. Auf Wochensicht summierten sich die Abschläge... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,030 | 0,00 % | Aktien New York: Dow mit schwachem Wochenauftakt - Nasdaq im Plus | NEW YORK (dpa-AFX) - An der Wall Street hat der Handel am Dienstag nach dem verlängerten Wochenende schwach begonnen. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst vor bald... ► Artikel lesen | |
| DISC MEDICINE | 65,24 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,320 | +0,03 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 280,81 | +0,01 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| TANGO THERAPEUTICS | 24,910 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 39,340 | 0,00 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 26,920 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| MODERNA | 174,30 | -0,13 % | Moderna-Aktie mit +35% - steht der Ausbruch bevor? | Die Moderna-Aktie hat gestern +12,27% zugelegt und notiert inzwischen bei 172,94 US$. Damit erreicht der Kurs eine entscheidende Widerstandszone. Während RSI und MACD eine starke Aufwärtsdynamik bestätigen... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 35,930 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 14,470 | 0,00 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population | After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with consistent and durable treatment burden reduction through 2 years 4D-150 continues to be well tolerated... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,615 | +0,03 % | Citizens reiterates Summit Therapeutics stock rating on trial data | ||
| CULLINAN THERAPEUTICS | 14,810 | 0,00 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio | Velinotamig (BCMA TCE) multi-dose regimen data in SLE at ACR Convergence 2026 in November CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA and Sjögren's disease in December CLN-049 (FLT3 TCE)... ► Artikel lesen | |
| IMMUNOME | 21,415 | +0,02 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| CLIMB BIO | 11,660 | 0,00 % | Climb Bio, Inc.: Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy | ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse... ► Artikel lesen |
BIOSERGEN AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,045 Euro und damit -1,11 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOSERGEN AB finden Sie auf Wallstreet Online.